rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BCRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BioCryst presents real-world data on ORLADEYO at ACAAI meeting
      Nov 13Investing.comBCRX
      The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
      Nov 11Yahoo FinanceBCRXINSMTGTX
      BioCryst Pharmaceuticals (BCRX) Raised Its Outlook, Is It Still Below Fair Value?

      BioCryst Pharmaceuticals (BCRX) stock is in focus after third quarter results showed revenue of US$180.29 million and net income of US$37.92 million, along with higher full year 2026 revenue guidance. Against that earnings backdrop, BioCryst Pharmaceuticals shares have been under pressure in recent months, with the 30 day share price return down 8.45% and the 90 day move down 18.02%. However, the year to date share price return is positive at 2.53% and the 3 year total shareholder return is...

      Nov 7Yahoo FinanceBCRX
      BioCryst Pharmaceuticals Inc (BCRX) (Q3 2026) Earnings Call Highlights: ORLADEYO Revenue Climbs ...
      Nov 5Yahoo FinanceBCRX
      BioCryst to Present at Upcoming Investor Conferences
      Nov 4Yahoo FinanceBCRX
      BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
      Nov 4Seeking AlphaBCRX
      BioCryst Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceBCRX
      BioCryst (BCRX) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 4The Globe and MailBCRX
      BioCryst Q3 2026 slides: HAE portfolio drives 70% profit jump
      Nov 4Investing.comBCRX
      Earnings call transcript: BioCryst tops Q3 2026 estimates as profit jumps
      Nov 4Investing.comBCRX
      BioCryst Pharmaceuticals Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceBCRX
      BioCryst Pharma Q3 2026 Earnings Call Transcript
      Nov 4BenzingaBCRX
      BioCryst earnings beat by $0.05, revenue topped estimates
      Nov 4Investing.comBCRX
      BioCryst: Q3 Earnings Snapshot

      (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Wednesday reported third-quarter earnings of $37.

      Nov 4Yahoo FinanceBCRX
      BioCryst Reports Third Quarter 2026 Financial Results

      — Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older — RESEARCH TRIANGLE P

      Nov 4Yahoo FinanceBCRX
      BioCryst earnings up next: Can momentum last after Q2 surge?
      Nov 3Investing.comBCRX
      How New HAE Data At BioCryst Pharmaceuticals Stock Has Changed Its Investment Story
      Oct 31Yahoo FinanceBCRX
      Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
      Oct 30Yahoo FinanceBCRX
      BioCryst to present HAE therapy data at medical meeting
      Oct 29Investing.comBCRX
      BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

      —New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE— RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that four abstracts from its hereditary angioedema (HAE) portfolio have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16. BioCryst will pres

      Oct 29Yahoo FinanceBCRX
      BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
      Oct 28Yahoo FinanceBCRXKRYS
      BioCryst to Report Third Quarter 2026 Financial Results on November 4
      Oct 21Yahoo FinanceBCRXKRYS
      BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ)
      Oct 21Seeking AlphaBCRX
      BioCryst wins FDA approval for ORLADEYO pellet formulation
      Oct 21Investing.comBCRX
      BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
      Oct 21Yahoo FinanceBCRX
      Wedbush Cuts Price Target on BioCryst Pharmaceuticals to $18 From $20, Keeps Outperform Rating
      Oct 19Yahoo FinanceBCRX
      BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?
      Oct 15Yahoo FinanceBCRX
      Bank of America Securities Keeps Their Buy Rating on BioCryst (BCRX)

      Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailBCRX
      RBC Capital Sticks to Its Hold Rating for BioCryst (BCRX)

      Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailBCRX
      BioCryst forms scientific advisory board for R&D strategy
      Oct 5Investing.comBCRX
      BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
      Oct 5Yahoo FinanceBCRX
      Claude AI Just Bought These 2 Pharma Stocks
      Sep 29Yahoo FinanceBCRX
      Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?
      Sep 23Yahoo FinanceBCRX
      Biopharma Stock With Layers of Technical Support in Place
      Sep 21Yahoo FinanceBCRX
      BioCryst Eyes $1B Rare-Disease Future Through External Innovation

      BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said

      Sep 19Yahoo FinanceBCRX
      BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs

      On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug “Orladeyo,” is looking to acquire more rare disease treatments, according to CEO Charlie Gayer. Gayer, who took the role in January, said the company expects to keep growing profits every year and does […]

      Sep 17Yahoo FinanceBCRX
      BioCryst at Morgan Stanley conference: pivots to external growth
      Sep 15Investing.comBCRXMS
      BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story

      BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceuticals, with the share price falling 18.47% over the past week and 16.63% over the past month, yet still showing an 8.27% year to date share price return and a 5.45% one year total shareholder return. This suggests that short term momentum is...

      Sep 14Yahoo FinanceBCRX
      BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX)
      Sep 11Seeking AlphaBCRX
      BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says
      Sep 10Yahoo FinanceBCRX
      CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio

      NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo® (berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1 “The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty

      Sep 8Yahoo FinanceBCRX
      TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
      Sep 8Investing.comBCRX
      BioCryst to Present at Upcoming Investor Conference

      RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biote

      Sep 1Yahoo FinanceBCRX
      Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?

      Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

      Aug 31Yahoo FinanceBCRX
      BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset

      CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.

      Aug 28Yahoo FinanceBCRX
      BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve (NASDAQ:BCRX)
      Aug 28Seeking AlphaBCRX
      Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet

      The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Aug 28Yahoo FinanceBCRX
      BioCryst is profitable. Now it wants to buy more rare disease drugs

      Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.

      Aug 28CNBCBCRX
      BioCryst gets Japan approval for HAE drug in young children
      Aug 25Investing.comBCRX
      BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

      — Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years. “The approval of ORL

      Aug 25Yahoo FinanceBCRX

      This is the newest page. Registered accounts read further back.